ctDNA predicts clinical T1a to pathological T3a upstaging after partial nephrectomy
Most patients diagnosed with clear cell renal cell carcinoma (ccRCC) are also detected with small and organ-confined tumors, and the majority of these are classified as clinical tumor stage 1a (cT1a). A considerable proportion of patients with cT1 RCC shows tumor upstaging to pathological stage 3a (...
Gespeichert in:
| Veröffentlicht in: | Cancer science 2024-05, Vol.115 (5), p.1680-1687 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1687 |
|---|---|
| container_issue | 5 |
| container_start_page | 1680 |
| container_title | Cancer science |
| container_volume | 115 |
| creator | Park, Jee Soo Kim, Hongkyung Jang, Won Sik Kim, Jongchan Ham, Won Sik Lee, Seung-Tae |
| description | Most patients diagnosed with clear cell renal cell carcinoma (ccRCC) are also detected with small and organ-confined tumors, and the majority of these are classified as clinical tumor stage 1a (cT1a). A considerable proportion of patients with cT1 RCC shows tumor upstaging to pathological stage 3a (pT3a), and these patients have worse oncological outcomes. The role of circulating tumor DNA (ctDNA) in RCC has been limited to monitoring treatment response and resistance. Therefore, the present study aimed to evaluate the potential of ctDNA in predicting pT3a upstaging in cT1a ccRCC. We sequenced plasma samples preoperatively collected from 48 patients who had undergone partial nephrectomy for cT1a ccRCC using data from a prospective cohort RCC. The ctDNA were profiled and compared with clinicopathological ccRCC features to predict pT3a upstaging. Associations between ctDNA, tumor complexity, and pT3a upstaging were evaluated. Tumor complexity was assessed using the anatomical classification system. Univariate analysis used chi-squared and Student's t-tests; multivariate analysis considered significant factors from univariate analyses. Of the 48 patients with cT1a ccRCC, 12 (25%) were upstaged to pT3a, with ctDNA detected in 10 (20.8%), predominantly in patients with renal sinus fat invasion (SFI; n = 8). Among the pT3a group, ctDNA was detected in 75%, contrasting with only 2.8% in patients with pT1a (1/36). Detection of ctDNA was the only significant preoperative predictor of pT3a upstaging, especially in SFI. This study is the first to suggest ctDNA as a preoperative predictor of pT3a RCC upstaging from cT1a based on preoperative radiological images. |
| doi_str_mv | 10.1111/cas.16146 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11093191</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2956687637</sourcerecordid><originalsourceid>FETCH-LOGICAL-c404t-ef9c4e23ddf19e3f78c20972f0df23243aff811b196d5baba9accfa33e19f1853</originalsourceid><addsrcrecordid>eNpdkU1PwzAMhiME4vvAH0CVuMChEDdZ25zQxLc0wQE4R16abEFdU5IUaf-ewAABvtiyH72y_RJyAPQUUpwpDKdQAi_XyDYwLvKK0nL9s65yQVmxRXZCeKGUlVzwTbLFal6NyhK2yaOKl_fjrPe6sSqGTLW2swrb7Akwiy7rMc5d62arHsNs6EPEme1mGZqofQJ8tGnW6X7utYpusdwjGwbboPe_8i55vr56urjNJw83dxfjSa445THXRiiuC9Y0BoRmpqpVQUVVGNqYghWcoTE1wBRE2YymOEWBShlkTIMwUI_YLjlf6fbDdKEbpbvosZW9twv0S-nQyr-Tzs7lzL1JACoYCEgKx18K3r0OOkS5sEHptsVOuyHIQqQv1VXJqoQe_UNf3OC7dJ9kdMQ5pyvqZEUp70Lw2vxsA1R-eCWTV_LTq8Qe_l7_h_w2h70D1riQQg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3054440637</pqid></control><display><type>article</type><title>ctDNA predicts clinical T1a to pathological T3a upstaging after partial nephrectomy</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Wiley-Blackwell Open Access Titles</source><source>Wiley Online Library All Journals</source><source>PubMed Central</source><creator>Park, Jee Soo ; Kim, Hongkyung ; Jang, Won Sik ; Kim, Jongchan ; Ham, Won Sik ; Lee, Seung-Tae</creator><creatorcontrib>Park, Jee Soo ; Kim, Hongkyung ; Jang, Won Sik ; Kim, Jongchan ; Ham, Won Sik ; Lee, Seung-Tae</creatorcontrib><description>Most patients diagnosed with clear cell renal cell carcinoma (ccRCC) are also detected with small and organ-confined tumors, and the majority of these are classified as clinical tumor stage 1a (cT1a). A considerable proportion of patients with cT1 RCC shows tumor upstaging to pathological stage 3a (pT3a), and these patients have worse oncological outcomes. The role of circulating tumor DNA (ctDNA) in RCC has been limited to monitoring treatment response and resistance. Therefore, the present study aimed to evaluate the potential of ctDNA in predicting pT3a upstaging in cT1a ccRCC. We sequenced plasma samples preoperatively collected from 48 patients who had undergone partial nephrectomy for cT1a ccRCC using data from a prospective cohort RCC. The ctDNA were profiled and compared with clinicopathological ccRCC features to predict pT3a upstaging. Associations between ctDNA, tumor complexity, and pT3a upstaging were evaluated. Tumor complexity was assessed using the anatomical classification system. Univariate analysis used chi-squared and Student's t-tests; multivariate analysis considered significant factors from univariate analyses. Of the 48 patients with cT1a ccRCC, 12 (25%) were upstaged to pT3a, with ctDNA detected in 10 (20.8%), predominantly in patients with renal sinus fat invasion (SFI; n = 8). Among the pT3a group, ctDNA was detected in 75%, contrasting with only 2.8% in patients with pT1a (1/36). Detection of ctDNA was the only significant preoperative predictor of pT3a upstaging, especially in SFI. This study is the first to suggest ctDNA as a preoperative predictor of pT3a RCC upstaging from cT1a based on preoperative radiological images.</description><identifier>ISSN: 1347-9032</identifier><identifier>EISSN: 1349-7006</identifier><identifier>DOI: 10.1111/cas.16146</identifier><identifier>PMID: 38475661</identifier><language>eng</language><publisher>England: John Wiley & Sons, Inc</publisher><subject>Adult ; Age ; Aged ; Aged, 80 and over ; Biomarkers, Tumor - blood ; Biomarkers, Tumor - genetics ; Cancer ; Carcinoma, Renal Cell - blood ; Carcinoma, Renal Cell - genetics ; Carcinoma, Renal Cell - pathology ; Carcinoma, Renal Cell - surgery ; Circulating Tumor DNA - blood ; Circulating Tumor DNA - genetics ; Clear cell-type renal cell carcinoma ; Data analysis ; Female ; Humans ; Kidney Neoplasms - blood ; Kidney Neoplasms - genetics ; Kidney Neoplasms - pathology ; Kidney Neoplasms - surgery ; Laparoscopy ; Male ; Medical prognosis ; Middle Aged ; Multivariate analysis ; Mutation ; Neoplasm Staging ; Nephrectomy ; Nephrectomy - methods ; Original ; ORIGINAL ARTICLES ; Pathology ; Patients ; Plasma ; Prospective Studies ; Risk factors ; Surgeons ; Tumors</subject><ispartof>Cancer science, 2024-05, Vol.115 (5), p.1680-1687</ispartof><rights>2024 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.</rights><rights>2024. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2024 The Authors. published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c404t-ef9c4e23ddf19e3f78c20972f0df23243aff811b196d5baba9accfa33e19f1853</citedby><cites>FETCH-LOGICAL-c404t-ef9c4e23ddf19e3f78c20972f0df23243aff811b196d5baba9accfa33e19f1853</cites><orcidid>0000-0003-2246-8838</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11093191/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11093191/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38475661$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Park, Jee Soo</creatorcontrib><creatorcontrib>Kim, Hongkyung</creatorcontrib><creatorcontrib>Jang, Won Sik</creatorcontrib><creatorcontrib>Kim, Jongchan</creatorcontrib><creatorcontrib>Ham, Won Sik</creatorcontrib><creatorcontrib>Lee, Seung-Tae</creatorcontrib><title>ctDNA predicts clinical T1a to pathological T3a upstaging after partial nephrectomy</title><title>Cancer science</title><addtitle>Cancer Sci</addtitle><description>Most patients diagnosed with clear cell renal cell carcinoma (ccRCC) are also detected with small and organ-confined tumors, and the majority of these are classified as clinical tumor stage 1a (cT1a). A considerable proportion of patients with cT1 RCC shows tumor upstaging to pathological stage 3a (pT3a), and these patients have worse oncological outcomes. The role of circulating tumor DNA (ctDNA) in RCC has been limited to monitoring treatment response and resistance. Therefore, the present study aimed to evaluate the potential of ctDNA in predicting pT3a upstaging in cT1a ccRCC. We sequenced plasma samples preoperatively collected from 48 patients who had undergone partial nephrectomy for cT1a ccRCC using data from a prospective cohort RCC. The ctDNA were profiled and compared with clinicopathological ccRCC features to predict pT3a upstaging. Associations between ctDNA, tumor complexity, and pT3a upstaging were evaluated. Tumor complexity was assessed using the anatomical classification system. Univariate analysis used chi-squared and Student's t-tests; multivariate analysis considered significant factors from univariate analyses. Of the 48 patients with cT1a ccRCC, 12 (25%) were upstaged to pT3a, with ctDNA detected in 10 (20.8%), predominantly in patients with renal sinus fat invasion (SFI; n = 8). Among the pT3a group, ctDNA was detected in 75%, contrasting with only 2.8% in patients with pT1a (1/36). Detection of ctDNA was the only significant preoperative predictor of pT3a upstaging, especially in SFI. This study is the first to suggest ctDNA as a preoperative predictor of pT3a RCC upstaging from cT1a based on preoperative radiological images.</description><subject>Adult</subject><subject>Age</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biomarkers, Tumor - blood</subject><subject>Biomarkers, Tumor - genetics</subject><subject>Cancer</subject><subject>Carcinoma, Renal Cell - blood</subject><subject>Carcinoma, Renal Cell - genetics</subject><subject>Carcinoma, Renal Cell - pathology</subject><subject>Carcinoma, Renal Cell - surgery</subject><subject>Circulating Tumor DNA - blood</subject><subject>Circulating Tumor DNA - genetics</subject><subject>Clear cell-type renal cell carcinoma</subject><subject>Data analysis</subject><subject>Female</subject><subject>Humans</subject><subject>Kidney Neoplasms - blood</subject><subject>Kidney Neoplasms - genetics</subject><subject>Kidney Neoplasms - pathology</subject><subject>Kidney Neoplasms - surgery</subject><subject>Laparoscopy</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Middle Aged</subject><subject>Multivariate analysis</subject><subject>Mutation</subject><subject>Neoplasm Staging</subject><subject>Nephrectomy</subject><subject>Nephrectomy - methods</subject><subject>Original</subject><subject>ORIGINAL ARTICLES</subject><subject>Pathology</subject><subject>Patients</subject><subject>Plasma</subject><subject>Prospective Studies</subject><subject>Risk factors</subject><subject>Surgeons</subject><subject>Tumors</subject><issn>1347-9032</issn><issn>1349-7006</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNpdkU1PwzAMhiME4vvAH0CVuMChEDdZ25zQxLc0wQE4R16abEFdU5IUaf-ewAABvtiyH72y_RJyAPQUUpwpDKdQAi_XyDYwLvKK0nL9s65yQVmxRXZCeKGUlVzwTbLFal6NyhK2yaOKl_fjrPe6sSqGTLW2swrb7Akwiy7rMc5d62arHsNs6EPEme1mGZqofQJ8tGnW6X7utYpusdwjGwbboPe_8i55vr56urjNJw83dxfjSa445THXRiiuC9Y0BoRmpqpVQUVVGNqYghWcoTE1wBRE2YymOEWBShlkTIMwUI_YLjlf6fbDdKEbpbvosZW9twv0S-nQyr-Tzs7lzL1JACoYCEgKx18K3r0OOkS5sEHptsVOuyHIQqQv1VXJqoQe_UNf3OC7dJ9kdMQ5pyvqZEUp70Lw2vxsA1R-eCWTV_LTq8Qe_l7_h_w2h70D1riQQg</recordid><startdate>20240501</startdate><enddate>20240501</enddate><creator>Park, Jee Soo</creator><creator>Kim, Hongkyung</creator><creator>Jang, Won Sik</creator><creator>Kim, Jongchan</creator><creator>Ham, Won Sik</creator><creator>Lee, Seung-Tae</creator><general>John Wiley & Sons, Inc</general><general>John Wiley and Sons Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>8FE</scope><scope>8FH</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-2246-8838</orcidid></search><sort><creationdate>20240501</creationdate><title>ctDNA predicts clinical T1a to pathological T3a upstaging after partial nephrectomy</title><author>Park, Jee Soo ; Kim, Hongkyung ; Jang, Won Sik ; Kim, Jongchan ; Ham, Won Sik ; Lee, Seung-Tae</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c404t-ef9c4e23ddf19e3f78c20972f0df23243aff811b196d5baba9accfa33e19f1853</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adult</topic><topic>Age</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biomarkers, Tumor - blood</topic><topic>Biomarkers, Tumor - genetics</topic><topic>Cancer</topic><topic>Carcinoma, Renal Cell - blood</topic><topic>Carcinoma, Renal Cell - genetics</topic><topic>Carcinoma, Renal Cell - pathology</topic><topic>Carcinoma, Renal Cell - surgery</topic><topic>Circulating Tumor DNA - blood</topic><topic>Circulating Tumor DNA - genetics</topic><topic>Clear cell-type renal cell carcinoma</topic><topic>Data analysis</topic><topic>Female</topic><topic>Humans</topic><topic>Kidney Neoplasms - blood</topic><topic>Kidney Neoplasms - genetics</topic><topic>Kidney Neoplasms - pathology</topic><topic>Kidney Neoplasms - surgery</topic><topic>Laparoscopy</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Middle Aged</topic><topic>Multivariate analysis</topic><topic>Mutation</topic><topic>Neoplasm Staging</topic><topic>Nephrectomy</topic><topic>Nephrectomy - methods</topic><topic>Original</topic><topic>ORIGINAL ARTICLES</topic><topic>Pathology</topic><topic>Patients</topic><topic>Plasma</topic><topic>Prospective Studies</topic><topic>Risk factors</topic><topic>Surgeons</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Park, Jee Soo</creatorcontrib><creatorcontrib>Kim, Hongkyung</creatorcontrib><creatorcontrib>Jang, Won Sik</creatorcontrib><creatorcontrib>Kim, Jongchan</creatorcontrib><creatorcontrib>Ham, Won Sik</creatorcontrib><creatorcontrib>Lee, Seung-Tae</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancer science</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Park, Jee Soo</au><au>Kim, Hongkyung</au><au>Jang, Won Sik</au><au>Kim, Jongchan</au><au>Ham, Won Sik</au><au>Lee, Seung-Tae</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>ctDNA predicts clinical T1a to pathological T3a upstaging after partial nephrectomy</atitle><jtitle>Cancer science</jtitle><addtitle>Cancer Sci</addtitle><date>2024-05-01</date><risdate>2024</risdate><volume>115</volume><issue>5</issue><spage>1680</spage><epage>1687</epage><pages>1680-1687</pages><issn>1347-9032</issn><eissn>1349-7006</eissn><abstract>Most patients diagnosed with clear cell renal cell carcinoma (ccRCC) are also detected with small and organ-confined tumors, and the majority of these are classified as clinical tumor stage 1a (cT1a). A considerable proportion of patients with cT1 RCC shows tumor upstaging to pathological stage 3a (pT3a), and these patients have worse oncological outcomes. The role of circulating tumor DNA (ctDNA) in RCC has been limited to monitoring treatment response and resistance. Therefore, the present study aimed to evaluate the potential of ctDNA in predicting pT3a upstaging in cT1a ccRCC. We sequenced plasma samples preoperatively collected from 48 patients who had undergone partial nephrectomy for cT1a ccRCC using data from a prospective cohort RCC. The ctDNA were profiled and compared with clinicopathological ccRCC features to predict pT3a upstaging. Associations between ctDNA, tumor complexity, and pT3a upstaging were evaluated. Tumor complexity was assessed using the anatomical classification system. Univariate analysis used chi-squared and Student's t-tests; multivariate analysis considered significant factors from univariate analyses. Of the 48 patients with cT1a ccRCC, 12 (25%) were upstaged to pT3a, with ctDNA detected in 10 (20.8%), predominantly in patients with renal sinus fat invasion (SFI; n = 8). Among the pT3a group, ctDNA was detected in 75%, contrasting with only 2.8% in patients with pT1a (1/36). Detection of ctDNA was the only significant preoperative predictor of pT3a upstaging, especially in SFI. This study is the first to suggest ctDNA as a preoperative predictor of pT3a RCC upstaging from cT1a based on preoperative radiological images.</abstract><cop>England</cop><pub>John Wiley & Sons, Inc</pub><pmid>38475661</pmid><doi>10.1111/cas.16146</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0003-2246-8838</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1347-9032 |
| ispartof | Cancer science, 2024-05, Vol.115 (5), p.1680-1687 |
| issn | 1347-9032 1349-7006 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11093191 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Wiley-Blackwell Open Access Titles; Wiley Online Library All Journals; PubMed Central |
| subjects | Adult Age Aged Aged, 80 and over Biomarkers, Tumor - blood Biomarkers, Tumor - genetics Cancer Carcinoma, Renal Cell - blood Carcinoma, Renal Cell - genetics Carcinoma, Renal Cell - pathology Carcinoma, Renal Cell - surgery Circulating Tumor DNA - blood Circulating Tumor DNA - genetics Clear cell-type renal cell carcinoma Data analysis Female Humans Kidney Neoplasms - blood Kidney Neoplasms - genetics Kidney Neoplasms - pathology Kidney Neoplasms - surgery Laparoscopy Male Medical prognosis Middle Aged Multivariate analysis Mutation Neoplasm Staging Nephrectomy Nephrectomy - methods Original ORIGINAL ARTICLES Pathology Patients Plasma Prospective Studies Risk factors Surgeons Tumors |
| title | ctDNA predicts clinical T1a to pathological T3a upstaging after partial nephrectomy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T08%3A39%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=ctDNA%20predicts%20clinical%20T1a%20to%20pathological%20T3a%20upstaging%20after%20partial%20nephrectomy&rft.jtitle=Cancer%20science&rft.au=Park,%20Jee%20Soo&rft.date=2024-05-01&rft.volume=115&rft.issue=5&rft.spage=1680&rft.epage=1687&rft.pages=1680-1687&rft.issn=1347-9032&rft.eissn=1349-7006&rft_id=info:doi/10.1111/cas.16146&rft_dat=%3Cproquest_pubme%3E2956687637%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3054440637&rft_id=info:pmid/38475661&rfr_iscdi=true |